Name: CLS on a Q3 characterised by US-advancement
Uploaded: 2022-11-23T09:15:25+01:00
Channel: Cecilia Hallström
Description: CLS' CEO Dan Mogren visited BioStock's studio to sum up the company's third quarter and look ahead to 2023.

CLS vd Dan Mogren i BioStocks studio i Lund

CLS on a Q3 characterised by US-advancement

23 November, 2022

ClearPoint Neuro delivers first order to CLS

21 October, 2022

Tag: ClearPoint Prism Neuro Laser Therapy System

CLS on a Q3 characterised by US-advancement

ClearPoint Neuro delivers first order to CLS